Glycopyrronium Bromide And Neostigmine Metilsulfate Martindale Pharmaceuticals (Glycopyrronium Bromide, Neostigmine Methylsulfate)

Glycopyrronium bromide and neostigmine methylsulfate is indicated for specific peri‑operative applications in patients undergoing general anesthesia.

• Reversal of non‑depolarizing neuromuscular blockade after surgery.
• Reduction of salivary, respiratory and gastrointestinal secretions during operative procedures.
• Facilitation of tracheal extubation by improving airway patency.
• Adjunct to anesthesia to maintain hemodynamic stability when rapid reversal is required.
• Use in patients where anticholinergic effects are desired to limit bradycardia associated with neostigmine.

The safety profile of the combination reflects the pharmacologic actions of both components.

Common

• Dry mouth and reduced salivation.
• Mild facial flushing.
• Transient tachycardia.
• Nausea or mild gastrointestinal discomfort.
• Muscle fasciculations or mild weakness during reversal.
• Dizziness or light‑headed feeling.

Serious

• Severe bradycardia or arrhythmias.
• Excessive muscarinic blockade leading to bronchospasm.
• Prolonged neuromuscular blockade.
• Allergic reactions such as urticaria, angioedema, or anaphylaxis.
• Seizure activity in susceptible individuals.
• Hyperkalemia in patients with renal impairment.

When prescribing glycopyrronium bromide and neostigmine methylsulfate, clinicians should consider several precautionary measures to ensure patient safety.

• Assess baseline heart rate and rhythm; anticholinergic effects may exacerbate tachyarrhythmias.
• Evaluate renal and hepatic function, as drug clearance can be altered.
• Use caution in patients with asthma or chronic obstructive pulmonary disease due to potential bronchial secretions changes.
• Avoid in individuals with known hypersensitivity to either component.
• Monitor neuromuscular function closely after administration to detect incomplete reversal.
• Consider dose adjustment in the elderly or frail patients.

The combination may interact with other medications that influence cholinergic pathways or cardiac conduction.

Avoid

• Concurrent use of other anticholinergic agents (e.g., atropine, scopolamine) that could amplify dry‑secretions and tachycardia.
• Potent reversible cholinesterase inhibitors (e.g., pyridostigmine) that may counteract neostigmine’s effect.

Use with caution

• Beta‑blockers or calcium‑channel blockers, as additive effects on heart rate may occur.
• Neuromuscular blocking agents, requiring careful timing to avoid prolonged paralysis.
• Drugs that prolong QT interval, given potential arrhythmic risk.
• Anesthetic gases that increase secretions, which may reduce the anticholinergic benefit.